HC Wainwright began coverage on shares of Harrow (NASDAQ:HROW - Free Report) in a research report sent to investors on Thursday, MarketBeat reports. The brokerage issued a buy rating and a $57.00 price objective on the stock.
Separately, B. Riley cut their target price on Harrow from $73.00 to $69.00 and set a "buy" rating for the company in a research note on Wednesday, December 4th.
Read Our Latest Stock Report on Harrow
Harrow Trading Down 0.1 %
HROW stock traded down $0.03 during mid-day trading on Thursday, hitting $31.01. 255,320 shares of the stock were exchanged, compared to its average volume of 319,571. The company has a current ratio of 1.55, a quick ratio of 1.44 and a debt-to-equity ratio of 3.23. The business has a fifty day moving average price of $34.78 and a 200 day moving average price of $39.62. Harrow has a 12 month low of $9.30 and a 12 month high of $59.23.
Institutional Inflows and Outflows
Large investors have recently modified their holdings of the stock. Quest Partners LLC purchased a new stake in Harrow during the 3rd quarter valued at about $29,000. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Harrow by 21.5% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,283 shares of the company's stock valued at $57,000 after purchasing an additional 227 shares during the period. Hills Bank & Trust Co purchased a new stake in shares of Harrow during the third quarter valued at approximately $107,000. AlphaQuest LLC grew its holdings in shares of Harrow by 452.8% in the fourth quarter. AlphaQuest LLC now owns 3,527 shares of the company's stock worth $118,000 after purchasing an additional 2,889 shares during the last quarter. Finally, Huntington National Bank purchased a new position in shares of Harrow in the third quarter worth $164,000. Hedge funds and other institutional investors own 72.76% of the company's stock.
Harrow Company Profile
(
Get Free Report)
Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.
See Also
Before you consider Harrow, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Harrow wasn't on the list.
While Harrow currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
